182 publications
Name | Date | Type | Actions |
---|---|---|---|
Q3 2018 sales: €90.2 million Vetoquinol wins second prize for CSR in the Gaia Rating In the first nine months of 2018, Vetoquinol recorded sales of €268.1 million, up 3.8% at constant exchange rates and 0.4% as reported. |
18/10/2018 | Public releases | |
Q3 2019 sales: €100.2 million (Up 11.0%) The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year. |
16/10/2019 | Public releases | |
Q3 2020 sales: €114.5 million* (Up 14.3%) Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year. |
15/10/2020 | Public releases | |
Rapport semestriel 2007 « narratif » (french) Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un |
31/08/2007 | Public releases | |
Redemption of tranche A bonds February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds. |
26/02/2010 | Public releases | |
Redemption of tranche B bonds Lure, 28 February 2011 – Vétoquinol S.A. has announced the redemption of the 58,927 tranche B bonds reaching maturity on 27 February 2011, by their conversion into common shares. |
28/02/2011 | Public releases | |
Reference products up +13.2%. net income up +9.3% Lure, March 23, 2015 – At its meeting on March 17, 2015, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the 2014 financial statements. |
23/03/2015 | Public releases | |
Reference products up 2.2% in Q1 2014 Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012. |
15/04/2014 | Public releases | |
Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017. |
27/07/2017 | Public releases | |
Reports very good first half, confirming that 2007 performance is set to surpass targets |
27/09/2007 | Public releases | |
Revenue grows by 10.3% in 2007, to €233.4 M |
24/01/2008 | Public releases | |
Revenues for the first nine months of 2008 Revenues increased by 3.1% during the first 9 months of 2008 to 171.2 million euros (4.8% on a like-for-like basis). |
22/10/2008 | Public releases | |
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
29/04/2024 | Public releases | |
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
26/10/2023 | Public releases | |
Sales momentum continues in Q3 Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year. |
25/10/2012 | Public releases | |
Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment. |
06/05/2008 | Public releases | |
September 2015 year-to-date sales up 8.7% to €251.8 million Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%. |
22/10/2015 | Public releases | |
September 2016 year-to-date sales: €257.5 million a 4.8% organic growth Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact. |
18/10/2016 | Public releases | |
Solid first half 2012 Sales First half 2012 sales reached €146.8 million, up 5.1% over first half 2011. |
17/07/2012 | Public releases | |
Solid growth in Q2 2014: 8.8% first half net income up 4.2% At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014. |
31/07/2014 | Public releases | |
Strong growth in 2009 Revenues: +7.6% January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions. |
20/01/2010 | Public releases | |
Strong growth in all key financial indicators in 2017 ebit up 9.4% to €46.0 million net income - group share up 25.2% to €34.8 million At its meeting on March 14, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2017 financial statements. |
15/03/2018 | Public releases | |
Strong growth in Revenues in the 3rd quarter Vétoquinol recorded strong growth in the 3rd quarter of 2009, despite an unfavourable exchange rate effect. The strength in sales was due to a combination of the contribution of acquisitions in Italy and India and sustained organic growth. |
14/10/2009 | Public releases | |
Strong Results in the first half of 2010 The Board of Directors of Vétoquinol, meeting on August 30, reviewed the group’s business and approved its interim 2010 financial statements. |
30/08/2010 | Public releases | |
Strong Revenue growth in the first quarter of 2012 Vétoquinol achieved Q1 2012 sales of €77.0 million, up 15.9% compared to Q1 2011. |
20/04/2012 | Public releases | |
Strong Sales in the 3rd Quarter of 2010 Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments. |
19/10/2010 | Public releases | |
Sustained revenue growth in 2006 |
15/02/2007 | Public releases | |
The reference products demonstrate solid growth Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013. |
29/08/2013 | Public releases | |
Third quarter revenues: €132 million |
14/10/2021 | Public releases | |
Vetimpress delivering digital solutions to farm vets with a growing network of partnerships September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions. |
21/09/2020 | Public releases | |
Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. |
13/11/2017 | Public releases | |
Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health. |
11/01/2021 | Public releases | |
Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. |
08/02/2021 | press release excluding results | |
Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction. |
16/04/2014 | Public releases | |
VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success. |
14/01/2010 | Public releases | |
Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China. |
13/12/2019 | Public releases | |
Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products. |
05/02/2015 | Public releases | |
Vetoquinol announces a new milestone in its industrial strategy Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners. |
12/07/2019 | Public releases | |
Vétoquinol announces opening of its first decentralized R&D center in Canada |
17/12/2007 | Public releases | |
November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as |
30/11/2010 | Public releases | |
Vétoquinol completes the acquisition of Wockhardt Animal Health in India August 20, 2009 (Lure, France) – Vétoquinol today announced the completion of its acquisition of the animal health business division of Wockhardt Limited, based in Mumbaï, India. This acquisition was the subject of an agreement signed with the Wockhardt Limited group on June 26. |
20/08/2009 | Public releases | |
Vétoquinol continues to develop its product ranges and enters the brazilian market Lure (France), August 30, 2011 – The Vetoquinol Board Meeting of August 29, 2011 reviewed the Group’s business and approved the financial statements for the first half 2011. |
30/08/2011 | Public releases | |
Vétoquinol continues to launch reference products Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States. |
16/12/2013 | Public releases | |
Vétoquinol creates a subsidiary in Portugal |
05/07/2007 | Public releases | |
VÉTOQUINOL enters the brazilian Market Lure (France), June 7, 2011 – Vetoquinol announces the acquisition of 100% of the equity of Farmagricola SA in Brazil. |
07/06/2011 | Public releases | |
Vétoquinol enters the indian market June 29, 2009 (Lure, France) – Vétoquinol today announced the signing of an agreement for the acquisition of the Animal Health Division of Wockhardt Limited, based in Mumbaï, India. |
29/06/2009 | Public releases | |
Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan. |
03/12/2015 | Public releases | |
Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.
|
16/04/2019 | Public releases | |
Vetoquinol finalizes the acquisition of Profender® and Drontal® product families September 1st, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1st, 2020. |
02/09/2020 | Public releases | |
Vétoquinol is eligible for new PEA-PME funds Lure (France), April 2, 2014 – Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME |
02/04/2014 | Public releases | |
Vétoquinol is eligible for new PEA-PME funds Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree |
23/05/2015 | Public releases | |
Vetoquinol is moving forward with the acquisition of Profender® and Drontal® and related pipeline assets following communication from the European commission June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health. |
09/06/2020 | Public releases | |
Vetoquinol launches its employer brand The veterinary pharmaceutical company Vetoquinol launches its employer brand. For 83 years, Vetoquinol has been building its future, drawing on relationships of trust with its partners, the development of every employee, and its long-held belief of continuous improvement. Following on from its corporate brand, the company is now positioning itself as a high-quality employer. |
29/09/2016 | Public releases | |
VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs. |
14/09/2015 | Public releases | |
Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is |
15/12/2010 | Public releases | |
Vétoquinol posts resilient results in the first half of 2009 and continues to pursue its international growth The Board of Directors of Vétoquinol, meeting on August 27, reviewed the group’s business and approved the group’s interim 2009 financial statements. |
31/08/2009 | Public releases | |
Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018 Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018 |
26/07/2018 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2009 (french version) The registration document of Vétoquinol relative to fiscal year 2009, including the annual financial report relative to fiscal year 2009, was registered with the Autorité des marchés financiers (“the AMF”) on April 22th, 2010. |
23/04/2010 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2010 (french version) The registration document of Vétoquinol relative to fiscal year 2010, including the annual financial report relative to fiscal year 2010, was registered with the Autorité des marchés financiers (“the AMF”) on April 18th, 2011. |
27/04/2011 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2011 (french version) The registration document of Vétoquinol relative to fiscal year 2011, including the annual financial report relative to fiscal year 2011, was registered with the Autorité des marchés financiers (“the AMF”) on April 20th, 2012. |
23/04/2012 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2012 (french version) The registration document of Vétoquinol relative to fiscal year 2012, including the annual financial report relative to fiscal year 2012, was registered with the Autorité des marchés financiers (“the AMF”) on April 15th, 2013. |
16/04/2013 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version) The registration document of Vétoquinol relative to fiscal year 2014, including the annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 17, 2015. |
20/04/2015 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version) The Registration document of Vetoquinol relative to fiscal year 2015, including the Annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 26, 2016. |
27/04/2016 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2016 (french version) The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017. |
26/04/2017 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2017 (french version) The registration document of Vetoquinol relative to fiscal year 2017, including the annual financial report relative to fiscal year 2017, was filed with the Autorité des marchés financiers (“the AMF”) on April 23, 2018. |
23/04/2018 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2018 (french version) The registration document of Vetoquinol relative to fiscal year 2018, including the annual financial report relative to fiscal year 2018, was filed with the Autorité des marchés financiers (“the AMF”) on April 29, 2019.
|
29/04/2019 | Public releases | |
Vétoquinol purchases ORSCO laboratoire vétérinaire Lure (France), September 25, 2012 – Vétoquinol announces the purchase of the entire equity of Orsco Laboratoire Vétérinaire. |
25/09/2012 | Public releases | |
Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing |
18/11/2010 | Public releases | |
Vétoquinol reports one of its industry’ strongest growth performances in 2006 |
03/04/2007 | Public releases | |
Vétoquinol returns to growth Lure (France), 29 August 2012 – At its 29 August 2012 meeting, the Vétoquinol S.A. board of directors reviewed the Group results and approved the financial statements for the first six months of 2012. |
29/08/2012 | Public releases | |
VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe |
17/03/2008 | Public releases | |
Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás. |
04/04/2019 | Public releases | |
Vétoquinol strengthens its position in Europe with the acquisition of Ascor Chimici in Italy Vétoquinol announces the signing of a contract to acquire 100 percent of the shares of Ascor Chimici S.r.l, which will take effect on 1 December 2008. |
25/11/2008 | Public releases | |
Vétoquinol strengthens its position in the United States |
02/01/2007 | Public releases | |
Vétoquinol strengthens its presence in Canada in the compagnion animal market Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC. The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada. |
01/07/2008 | Public releases | |
Vetoquinol takes a major step towards digital innovation by acquiring an equity interest in Farmvet Systems Ltd Vetoquinol, a leading global animal health company, has acquired a majority interest in Farmvet Systems Ltd. A thriving start-up based in Northern Ireland, Farmvet Systems digital know-how enables the strengthening of the role of the veterinary practitioner on cattle farms. |
06/09/2018 | Public releases | |
Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health. |
12/02/2020 | Public releases | |
Vétoquinol to acquire the animal health business of Bioniche Life Sciences Inc. LURE, FRANCE and BELLEVILLE, ONTARIO, CANADA, February 27, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche’s Animal Health business for the cash purchase price of CAD$61 million. |
27/02/2014 | Public releases | |
Vétoquinol to market and distribute Vetprofen in the United States |
28/11/2007 | Public releases | |
Vetoquinol wins the Animal Pharm’s award for best European company 2020 February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm. |
08/02/2021 | Public releases | |
VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare. |
28/09/2020 | Public releases | |
Vétoquinol: 2008 results expected to be in line with objectives At its meeting of 25 August 2008, the Board of Directors of Vétoquinol S.A. reviewed the Group’s operations and approved the financial statements for |
27/08/2008 | Public releases |